Wall Street brokerages forecast that Blueprint Medicines Corp (NASDAQ:BPMC) will post earnings per share of ($1.55) for the current quarter, according to Zacks. Three analysts have made estimates for Blueprint Medicines’ earnings. The highest EPS estimate is ($1.33) and the lowest is ($1.73). Blueprint Medicines posted earnings per share of ($0.96) in the same quarter last year, which suggests a negative year-over-year growth rate of 61.5%. The company is scheduled to announce its next quarterly earnings results on Tuesday, October 30th.

On average, analysts expect that Blueprint Medicines will report full-year earnings of ($5.13) per share for the current fiscal year, with EPS estimates ranging from ($5.61) to ($4.58). For the next financial year, analysts expect that the firm will report earnings of ($7.18) per share, with EPS estimates ranging from ($9.78) to ($5.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.70. Blueprint Medicines had a negative net margin of 326.99% and a negative return on equity of 32.61%. The business had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $2.62 million. During the same period last year, the business earned ($0.86) earnings per share. The firm’s revenue was up 602.9% on a year-over-year basis.

Several equities analysts recently weighed in on BPMC shares. JMP Securities decreased their target price on shares of Blueprint Medicines from $109.00 to $103.00 and set a “buy” rating for the company in a research note on Monday, June 4th. Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, May 7th. Wedbush raised their target price on shares of Blueprint Medicines from $98.00 to $106.00 and gave the company an “outperform” rating in a research note on Monday, April 16th. BidaskClub cut shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Tuesday, April 24th. Finally, ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $87.20.

In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $70.59, for a total transaction of $1,411,800.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at approximately $1,411,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.15% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Swiss National Bank lifted its holdings in Blueprint Medicines by 3.9% during the 1st quarter. Swiss National Bank now owns 67,200 shares of the biotechnology company’s stock valued at $6,162,000 after purchasing an additional 2,500 shares during the last quarter. Lisanti Capital Growth LLC lifted its holdings in shares of Blueprint Medicines by 29.4% during the first quarter. Lisanti Capital Growth LLC now owns 24,860 shares of the biotechnology company’s stock worth $2,280,000 after buying an additional 5,650 shares in the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Blueprint Medicines by 1,015.8% during the first quarter. Alkeon Capital Management LLC now owns 111,575 shares of the biotechnology company’s stock worth $10,231,000 after buying an additional 101,575 shares in the last quarter. Zeke Capital Advisors LLC acquired a new stake in shares of Blueprint Medicines during the first quarter worth $207,000. Finally, Guggenheim Capital LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $2,739,000. 97.60% of the stock is owned by institutional investors and hedge funds.

Blueprint Medicines opened at $68.86 on Thursday, MarketBeat Ratings reports. Blueprint Medicines has a 1-year low of $41.41 and a 1-year high of $109.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.36 and a current ratio of 12.36.

About Blueprint Medicines

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.